Around 600,000 bottles of Ramipril, a blood pressure medication, are being recalled due to potential contamination from ingredients sourced by an unregulated manufacturer in India. The recall affects 2.5 mg, 5 mg, and 10 mg capsules made by Lupin Pharmaceuticals,
sold in bottles with sell-by dates up to July 2026. While the FDA believes the risk is low and no adverse effects have been reported, users should dispose of any affected bottles. The recall is classified as a class 2, meaning it poses a moderate risk but is not considered life-threatening.